
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
- Authors:
- Saqer S. Alotaibi
- Essam H. Eldrehmy
- Sarah M. Albogami
- Adel Alkhedaide
- Omima Dahab
-
Affiliations: Department of Biotechnology, College of Science, Taif University, Taif 21944, Kingdom of Saudi Arabia, Department of Clinical Laboratory Sciences, Turabah College, Taif University, Turabah 29734, Kingdom of Saudi Arabia, Department of Biology, Turabah College, Taif University, Turabah 29734, Kingdom of Saudi Arabia - Published online on: June 25, 2025 https://doi.org/10.3892/etm.2025.12912
- Article Number: 162
-
Copyright: © Alotaibi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].
This article is mentioned in:
Abstract
![]() |
![]() |
Safaei M, Sundararajan EA, Driss M, Boulila W and Shapi'i A: A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 136(104754)2021.PubMed/NCBI View Article : Google Scholar | |
Konttinen H: Emotional eating and obesity in adults: The role of depression, sleep and genes. Proc Nutr Soc. 79:283–289. 2020.PubMed/NCBI View Article : Google Scholar | |
Tappia PS and Defries D: Prevalence, consequences, causes and management of obesity. In: Pathophysiology of Obesity-Induced Health Complications. Springer, Heidelberg, pp3-22, 2020. | |
Omer T: The causes of obesity: An in-depth review. Adv Obes Weight Manag Control. 10:90–94. 2020. | |
Franco M, Orduñez P, Caballero B, Tapia Granados JA, Lazo M, Bernal JL, Guallar E and Cooper RS: Impact of energy intake, physical activity, and population-wide weight loss on cardiovascular disease and diabetes mortality in Cuba, 1980-2005. Am J Epidemiol. 166:1374–1380. 2007.PubMed/NCBI View Article : Google Scholar | |
Popoviciu MS, Păduraru L, Yahya G, Metwally K and Cavalu S: Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials. Int J Mol Sci. 24(10449)2023.PubMed/NCBI View Article : Google Scholar | |
Lebovitz HE and Banerji MA: Point: Visceral adiposity is causally related to insulin resistance. Diabetes Care. 28:2322–2325. 2005.PubMed/NCBI View Article : Google Scholar | |
Crowley N, Arlinghaus KR and Myers ES: Dietary management of overweight and obesity. In: Lifestyle Medicine. 3rd edition. CRC Press, pp483-489, 2019. | |
Hotamisligil GS: Inflammation and metabolic disorders. Nature. 444:860–867. 2006.PubMed/NCBI View Article : Google Scholar | |
Maurizi G, Della Guardia L, Maurizi A and Poloni A: Adipocytes properties and crosstalk with immune system in obesity-related inflammation. J Cell Physiol. 233:88–97. 2018.PubMed/NCBI View Article : Google Scholar | |
Herman MA, Peroni OD, Villoria J, Schön MR, Abumrad NA, Blüher M, Klein S and Kahn BB: A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature. 484:333–338. 2012.PubMed/NCBI View Article : Google Scholar | |
Grundy SM: Metabolic complications of obesity. Endocrine. 13:155–165. 2000.PubMed/NCBI View Article : Google Scholar | |
Mahapatra MK, Karuppasamy M and Sahoo BM: Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 23:521–539. 2022.PubMed/NCBI View Article : Google Scholar | |
Lutter M and Nestler EJ: Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr. 139:629–632. 2009.PubMed/NCBI View Article : Google Scholar | |
Ferrario CR, Labouèbe G, Liu S, Nieh EH, Routh VH, Xu S and O'Connor EC: Homeostasis meets motivation in the battle to control food intake. J Neurosci. 36:11469–11481. 2016.PubMed/NCBI View Article : Google Scholar | |
Welle S and Campbell RG: Stimulation of thermogenesis by carbohydrate overfeeding. Evidence against sympathetic nervous system mediation. J Clin Invest. 71:916–925. 1983.PubMed/NCBI View Article : Google Scholar | |
Young JB and Landsberg L: Suppression of sympathetic nervous system during fasting. Obes Res. 5:646–649. 1997.PubMed/NCBI View Article : Google Scholar | |
Hesse S, van de Giessen E, Zientek F, Petroff D, Winter K, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Darcourt J, et al: Association of central serotonin transporter availability and body mass index in healthy Europeans. Eur Neuropsychopharmacol. 24:1240–1247. 2014.PubMed/NCBI View Article : Google Scholar | |
Blum K, Thanos PK and Gold MS: Dopamine and glucose, obesity, and reward deficiency syndrome. Front Psychol. 5(919)2014.PubMed/NCBI View Article : Google Scholar | |
English PJ, Ghatei MA, Malik IA, Bloom SR and Wilding JPH: Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 87(2984)2002.PubMed/NCBI View Article : Google Scholar | |
El-Haschimi K, Pierroz DD, Hileman SM, Bjørbæk C and Flier JS: Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 105:1827–1832. 2000.PubMed/NCBI View Article : Google Scholar | |
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH and Still CD: Endocrine Society. Pharmacological management of obesity: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 100:342–362. 2015.PubMed/NCBI View Article : Google Scholar | |
Obesity WHOJIAftSo, International Obesity Task Force TA-Ppro and treatment i: Regional Office for the Western Pacific, 2000. | |
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, et al: Clinical characteristics of Covid-19 in New York city. N Engl J Med. 382:2372–2374. 2020.PubMed/NCBI View Article : Google Scholar | |
Nakeshbandi M, Maini R, Daniel P, Rosengarten S, Parmar P, Wilson C, Kim JM, Oommen A, Mecklenburg M, Salvani J, et al: The impact of obesity on COVID-19 complications: A retrospective cohort study. Int J Obes (Lond). 44:1832–1837. 2020.PubMed/NCBI View Article : Google Scholar | |
Haupt TH, Kallemose T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, Pisinger C and Eugen-Olsen J: Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 9:91–100. 2014.PubMed/NCBI View Article : Google Scholar | |
Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahl K and Blomberg BB: Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS One. 16(e0245424)2021.PubMed/NCBI View Article : Google Scholar | |
Bell GI, Sanchez-Pescador R, Laybourn PJ and Najarian RCJN: Exon duplication and divergence in the human preproglucagon gene. Nature. 304:368–371. 1983.PubMed/NCBI View Article : Google Scholar | |
Gutniak M, Orskov C, Holst JJ, Ahrén B and Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 326:1316–1322. 1992.PubMed/NCBI View Article : Google Scholar | |
Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D and Porter L: DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet. 372:1240–1250. 2008.PubMed/NCBI View Article : Google Scholar | |
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, et al: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 18:3–14. 2018.PubMed/NCBI View Article : Google Scholar | |
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R and Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 91:301–307. 1993.PubMed/NCBI View Article : Google Scholar | |
Holst JJ: Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent? J Intern Med. 291:557–573. 2022.PubMed/NCBI View Article : Google Scholar | |
Kim HS and Jung CH: Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: Could it be a magic bullet for type 2 diabetes? Int J Mol Sci. 22(9936)2021.PubMed/NCBI View Article : Google Scholar | |
Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA and Kim AM: Danuglipron (PF-06882961) in type 2 diabetes: A randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 27:1079–1087. 2021.PubMed/NCBI View Article : Google Scholar | |
Xia L, Shen T, Dong W, Su F, Wang J, Wang Q, Niu S and Fang Y: Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract. 177(108904)2021.PubMed/NCBI View Article : Google Scholar | |
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, et al: Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 5(e133429)2020.PubMed/NCBI View Article : Google Scholar | |
Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, et al: The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 124:4473–4488. 2014.PubMed/NCBI View Article : Google Scholar | |
Brandt SJ, Müller TD, DiMarchi RD, Tschöp MH and Stemmer K: Peptide-based multi-agonists: A new paradigm in metabolic pharmacology. J Intern Med. 284:581–602. 2018.PubMed/NCBI View Article : Google Scholar | |
Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C and Rubino D: Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. Obesity (Silver Spring). 28:529–536. 2020.PubMed/NCBI View Article : Google Scholar | |
Müller TD, Blüher M, Tschöp MH and DiMarchi RD: Anti-obesity drug discovery: Advances and challenges. Nat Rev Drug Discov. 21:201–223. 2022.PubMed/NCBI View Article : Google Scholar | |
Lin CH, Shao L, Zhang YM, Tu YJ, Zhang Y, Tomlinson B, Chan P and Liu Z: An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother. 21:275–285. 2020.PubMed/NCBI View Article : Google Scholar | |
Kela R, Khunti K and Davies MJ: Liraglutide for type 2 diabetes mellitus. Expert Opin Biol Ther. 11:951–959. 2011.PubMed/NCBI View Article : Google Scholar | |
Gallwitz B: Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: Current and emerging agents. Drugs. 71:1675–1688. 2011.PubMed/NCBI View Article : Google Scholar | |
Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, et al: 3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial. Lancet. 389:1399–1409. 2017.PubMed/NCBI View Article : Google Scholar | |
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, et al: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 373:11–22. 2015.PubMed/NCBI View Article : Google Scholar | |
Grill HJ: A role for GLP-1 in treating hyperphagia and obesity. Endocrinology. 161(bqaa093)2020.PubMed/NCBI View Article : Google Scholar | |
Hall S, Isaacs D and Clements JN: Pharmacokinetics and clinical implications of semaglutide: A new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet. 57:1529–1538. 2018.PubMed/NCBI View Article : Google Scholar | |
Christou GA, Katsiki N, Blundell J, Fruhbeck G and Kiortsis DN: Semaglutide as a promising antiobesity drug. Obes Rev. 20:805–815. 2019.PubMed/NCBI View Article : Google Scholar | |
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, et al: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 384:989–1002. 2021.PubMed/NCBI View Article : Google Scholar | |
Knudsen LB and Lau J: The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 10(155)2019.PubMed/NCBI View Article : Google Scholar | |
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, et al: 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care. 46 (Suppl 1):S140–S157. 2023.PubMed/NCBI View Article : Google Scholar | |
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, et al: Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 58:7370–7380. 2015.PubMed/NCBI View Article : Google Scholar | |
Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, Madsen KG, Schéele SG, Alanentalo T, Kirk RK, et al: Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 10(eaar7047)2018.PubMed/NCBI View Article : Google Scholar | |
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL and Haluzík M: PIONEER 1 Investigators. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 42:1724–1732. 2019.PubMed/NCBI View Article : Google Scholar | |
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, et al: Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 389:877–888. 2023.PubMed/NCBI View Article : Google Scholar | |
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OK, Jabbour S and Rosenstock J: Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial. JAMA. 318:1460–1470. 2017.PubMed/NCBI View Article : Google Scholar | |
Reusch JE, Rosenstock J, Bush MA, Yang F and Stewart MW: Albiglutide, a long-acting GLP-1 receptor agonist, improves glycemia in type 2 diabetes: Time-course analysis. In: American Diabetes Association, pA123, 2009. | |
Ørskov C, Poulsen SS, Mørten M and Holst JJ: Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 45:832–835. 1996.PubMed/NCBI View Article : Google Scholar | |
Rosenstock J, Reusch J, Bush M, Yang F and Stewart M: Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 32:1880–1886. 2009.PubMed/NCBI View Article : Google Scholar | |
Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, et al: Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 26:287–296. 2010.PubMed/NCBI View Article : Google Scholar | |
Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, et al: The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 33:833–844.e5. 2021.PubMed/NCBI View Article : Google Scholar | |
Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K and Ellis B: LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 13:434–438. 2011.PubMed/NCBI View Article : Google Scholar | |
Umpierrez G, Blevins T, Rosenstock J, Cheng C, Anderson JH and Bastyr EJ III: EGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: The EGO study. Diabetes Obes Metab. 13:418–425. 2011.PubMed/NCBI View Article : Google Scholar | |
Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG and Weyer C: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 12:661–668. 2004.PubMed/NCBI View Article : Google Scholar | |
Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A and Lau DCW: Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: A randomised, controlled, phase 1b trial. Lancet. 397:1736–1748. 2021.PubMed/NCBI View Article : Google Scholar | |
Boyle CN, Lutz TA and Le Foll C: Amylin-its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 8:203–210. 2018.PubMed/NCBI View Article : Google Scholar | |
Ling W, Huang YM, Qiao YC, Zhang XX and Zhao HL: Human amylin: From pathology to physiology and pharmacology. Curr Protein Pept Sci. 20:944–957. 2019.PubMed/NCBI View Article : Google Scholar | |
Day C: Amylin analogue as an antidiabetic agent. Br J Diabetes Vasc Dis. 5:151–154. 2005. | |
Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE and Weyer C: Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 17:1736–1743. 2009.PubMed/NCBI View Article : Google Scholar | |
Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, et al: Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 64:11183–11194. 2021.PubMed/NCBI View Article : Google Scholar | |
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D and Batterham RL: Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 398:2160–2172. 2021.PubMed/NCBI View Article : Google Scholar | |
Sidrak WR, Kalra S and Kalhan A: Approved and emerging hormone-based anti-obesity medications: A review article. Indian J Endocrinol Metab. 28:445–460. 2024.PubMed/NCBI View Article : Google Scholar | |
Kaneko K, Fu Y, Lin HY, Cordonier EL, Mo Q, Gao Y, Yao T, Naylor J, Howard V, Saito K, et al: Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J Clin Invest. 129:3786–3791. 2019.PubMed/NCBI View Article : Google Scholar | |
Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD and Perez-Tilve D: Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab. 20:51–62. 2019.PubMed/NCBI View Article : Google Scholar | |
Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, et al: Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 30:987–996.e6. 2019.PubMed/NCBI View Article : Google Scholar | |
Borner T, Workinger JL, Tinsley IC, Fortin SM, Stein LM, Chepurny OG, Holz GG, Wierzba AJ, Gryko D, Nexø E, et al: Corrination of a GLP-1 receptor agonist for glycemic control without emesis. Cell Rep. 31(107768)2020.PubMed/NCBI View Article : Google Scholar | |
Samms RJ, Coghlan MP and Sloop KW: How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 31:410–421. 2020.PubMed/NCBI View Article : Google Scholar | |
Holst JJ and Rosenkilde MM: GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. J Clin Endocrinol Metab. 105:e2710–e2716. 2020.PubMed/NCBI View Article : Google Scholar | |
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA and Thieu VT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. Lancet. 398:143–155. 2021.PubMed/NCBI View Article : Google Scholar | |
Taylor R, Beveridge D and Fuller PJ: Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. Biochem J. 286:737–741. 1992.PubMed/NCBI View Article : Google Scholar | |
Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J and Roz C: Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch. 438:299–306. 1999.PubMed/NCBI View Article : Google Scholar | |
Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ and Christiansen J: Oxyntomodulin: A potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest. 18:499–503. 1988.PubMed/NCBI View Article : Google Scholar | |
Hoentjen F, Hopman WP and Jansen JB: Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol. 36:1086–1091. 2001.PubMed/NCBI View Article : Google Scholar | |
Tang-Christensen M, Vrang N and Larsen PJ: Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord. 25 (Suppl 5):S42–S47. 2001.PubMed/NCBI View Article : Google Scholar | |
Holst JJ: Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab. 10:229–235. 1999.PubMed/NCBI View Article : Google Scholar | |
Baldissera FG and Holst JJ: Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia. 26:223–228. 1984.PubMed/NCBI View Article : Google Scholar | |
Glover I, Haneef I, Pitts J, Wood S, Moss D, Tickle I and Blundell T: Conformational flexibility in a small globular hormone: X-ray analysis of avian pancreatic polypeptide at 0.98-A resolution. Biopolymers. 22:293–304. 1983.PubMed/NCBI View Article : Google Scholar | |
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM and Bloom SR: Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 89:1070–1077. 1985.PubMed/NCBI View Article : Google Scholar | |
Ekblad E and Sundler F: Distribution of pancreatic polypeptide and peptide YY. Peptides. 23:251–261. 2002.PubMed/NCBI View Article : Google Scholar | |
Christoffersen BØ, Sanchez-Delgado G, John LM, Ryan DH, Raun K and Ravussin E: Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity (Silver Spring). 30:841–857. 2022.PubMed/NCBI View Article : Google Scholar | |
Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, et al: A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 21:27–36. 2015.PubMed/NCBI View Article : Google Scholar | |
Sass F, Ma T, Ekberg JH, Kirigiti M, Ureña MG, Dollet L, Brown JM, Basse AL, Yacawych WT, Burm HB, et al: NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature. 635:987–1000. 2024.PubMed/NCBI View Article : Google Scholar | |
Speakman JR, de Jong JMA, Sinha S, Westerterp KR, Yamada Y, Sagayama H, Ainslie PN, Anderson LJ, Arab L, Bedu-Addo K, et al: Total daily energy expenditure has declined over the past three decades due to declining basal expenditure, not reduced activity expenditure. Nat Metab. 5:579–588. 2023.PubMed/NCBI View Article : Google Scholar | |
Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB and Gloriam DE: Trends in GPCR drug discovery: New agents, targets and indications. Nat Rev Drug Discov. 16:829–842. 2017.PubMed/NCBI View Article : Google Scholar | |
Brown JC, Mutt V and Pederson RA: Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol. 209:57–64. 1970.PubMed/NCBI View Article : Google Scholar | |
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M and Blonde L: LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 374:39–47. 2009.PubMed/NCBI View Article : Google Scholar | |
Meier JJ: GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 8:728–742. 2012.PubMed/NCBI View Article : Google Scholar | |
Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF and Lean ME: NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 374:1606–1616. 2009.PubMed/NCBI View Article : Google Scholar | |
Jastreboff AM, Aronne LJ and Stefanski A: Tirzepatide once weekly for the treatment of obesity. Reply. N Engl J Med. 387:1434–1435. 2022.PubMed/NCBI View Article : Google Scholar | |
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X and Brown K: SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 385:503–515. 2021.PubMed/NCBI View Article : Google Scholar | |
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, et al: Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 28:2083–2091. 2022.PubMed/NCBI View Article : Google Scholar | |
Chao AM, Tronieri JS, Amaro A and Wadden TA: Clinical insight on semaglutide for chronic weight management in adults: Patient selection and special considerations. Drug Des Devel Ther. 16:4449–4461. 2022.PubMed/NCBI View Article : Google Scholar | |
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ and Buse JB: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 41:2669–2701. 2018.PubMed/NCBI View Article : Google Scholar | |
Torbahn G, Lischka J, Brown T, Ells LJ, Kelly AS, Wabitsch M and Weghuber D: Anti-obesity medication in the management of children and adolescents with obesity: Recent developments and research gaps. Clin Endocrinol (Oxf). 102:51–61. 2025.PubMed/NCBI View Article : Google Scholar | |
Torbahn G, Jones A, Griffiths A, Matu J, Metzendorf MI, Ells LJ, Gartlehner G, Kelly AS, Weghuber D and Brown T: Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses. Pediatr Obes. 19(e13113)2024.PubMed/NCBI View Article : Google Scholar | |
van Boxel EJ, Rahman S, Lai K, Boulos N and Davis N: Semaglutide treatment for children with obesity: An observational study. Arch Dis Child. 109:822–825. 2024.PubMed/NCBI View Article : Google Scholar | |
Nedunchezhiyan U, Varughese I, Sun AR, Wu X, Crawford R and Prasadam I: Obesity, inflammation, and immune system in osteoarthritis. Front Immunol. 13(907750)2022.PubMed/NCBI View Article : Google Scholar | |
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, et al: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation. 129 (Suppl 2):S102–S138. 2014.PubMed/NCBI View Article : Google Scholar | |
Ryan DH and Yockey SR: Weight loss and improvement in comorbidity: Differences at 5, 10, 15%, and over. Curr Obes Rep. 6:187–194. 2017.PubMed/NCBI View Article : Google Scholar | |
Roseti L, Desando G, Cavallo C, Petretta M and Grigolo B: Articular cartilage regeneration in osteoarthritis. Cells. 8(1305)2019.PubMed/NCBI View Article : Google Scholar | |
Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM and Eisenberg MJ: Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. Am J Med: Jan 31, 2025 (Epub ahead of print). | |
Petrongolo G: Liraglutide and cardiovascular outcomes in diabetes (LEADER)-2016. In: Top Articles in Primary Care. Russell J and Skolnik NS (eds). Springer International Publishing, Cham, pp91-94, 2023. | |
Bhagavathula AS, Vidyasagar K and Tesfaye W: Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized phase II/III trials. Pharmaceuticals (Basel). 14(991)2021.PubMed/NCBI View Article : Google Scholar | |
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB and DeFronzo RA: NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA. 314:687–699. 2015.PubMed/NCBI View Article : Google Scholar | |
Westermeier F and Fisman EZ: Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: Historical development and future challenges. Cardiovasc Diabetol. 24(118)2025.PubMed/NCBI View Article : Google Scholar | |
Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, et al: Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a diabetes care editors' expert forum. Diabetes Care. 41:14–31. 2018.PubMed/NCBI View Article : Google Scholar | |
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 375:311–322. 2016.PubMed/NCBI View Article : Google Scholar | |
Helmstädter J, Keppeler K, Küster L, Münzel T, Daiber A and Steven S: Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor. Br J Pharmacol. 179:659–676. 2022.PubMed/NCBI View Article : Google Scholar | |
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey R, Deaton C, Cuisset T, et al: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European SOCIETY OF CARDIOlogy (ESC). Eur Heart J. 41:407–477. 2020. | |
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1):S98–S110. 2020.PubMed/NCBI View Article : Google Scholar | |
Marty VN, Farokhnia M, Munier JJ, Mulpuri Y, Leggio L and Spigelman I: Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci. 14(599646)2020.PubMed/NCBI View Article : Google Scholar | |
Klausen MK, Thomsen M, Wortwein G and Fink-Jensen A: The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 179:625–641. 2022.PubMed/NCBI View Article : Google Scholar | |
Graham DL, Erreger K, Galli A and Stanwood GD: GLP-1 analog attenuates cocaine reward. Mol Psychiatry. 18:961–962. 2013.PubMed/NCBI View Article : Google Scholar | |
Egecioglu E, Engel JA and Jerlhag E: The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 8(e69010)2013.PubMed/NCBI View Article : Google Scholar | |
Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD and Galli A: Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav. 106:574–578. 2012.PubMed/NCBI View Article : Google Scholar | |
Chaves Filho AJM, Cunha NL, de Souza AG, Soares MV, Jucá PM, de Queiroz T, Oliveira JVS, Valvassori SS, Barichello T, Quevedo J, et al: The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 99(109872)2020.PubMed/NCBI View Article : Google Scholar | |
Al-Nozha MM, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, Al-Marzouki K, Al-Mazrou YY, Abdullah M, Al-Khadra A, Al-Harthi SS, et al: Hyperlipidemia in Saudi Arabia. Saudi Med J. 29:282–287. 2008.PubMed/NCBI | |
Okati-Aliabad H, Ansari-Moghaddam A, Kargar S and Jabbari N: Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: A systematic review and meta-analysis. J Obes. 2022(8074837)2022.PubMed/NCBI View Article : Google Scholar | |
Alshaikh A, Aljedai A, Alfadda A, Alrobayan A, Bawahab A, Ouf SA, Sultan A, Alhozali A, Bawazeer M, Sheshah E, et al: Clinical practice guideline for the management of overweight and obesity in adults in Saudi Arabia. Int J Clin Med. 13:590–649. 2022. | |
World Health Organization: Saudi Arabia health profile 2015. World Health Organization. Regional Office for the Eastern Mediterranean, 2016. | |
Memish ZA, El Bcheraoui C, Tuffaha M, Robinson M, Daoud F, Jaber S, Mikhitarian S, Al Saeedi M, AlMazroa MA, Mokdad AH and Al Rabeeah AA: Obesity and associated factors-Kingdom of Saudi Arabia, 2013. Prev Chronic Dis. 11(E174)2014.PubMed/NCBI View Article : Google Scholar | |
Al-Omar HA, Alshehri A, Alqahtani SA, Alabdulkarim H, Alrumaih A and Eldin MS: A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities. Saudi Pharm J. 32(102192)2024.PubMed/NCBI View Article : Google Scholar | |
Bin Horaib G, Al-Khashan HI, Mishriky AM, Selim MA, Alnowaiser N, Binsaeed AA, Alawad AD, Al-Asmari AK and Alqumaizi K: Prevalence of obesity among military personnel in Saudi Arabia and associated risk factors. Saudi Med J. 34:401–407. 2013.PubMed/NCBI | |
Malkin JD, Baid D, Alsukait RF, Alghaith T, Alluhidan M, Alabdulkarim H, Altowaijri A, Almalki ZS, Herbst CH, Finkelstein EA, et al: The economic burden of overweight and obesity in Saudi Arabia. PLoS One. 17(e0264993)2022.PubMed/NCBI View Article : Google Scholar | |
Alluhidan M, Alsukait R, Alghaith T, Shekar M and Herbst C: Overweight and obesity in Saudi Arabia: Consequences and solutions. World Bank Publications, Washington, DC, 2022. | |
Aldubayan K and Murimi M: Compliance with school nutrition policy in Saudi Arabia: A quantitative study. East Mediterr Health J. 25:230–238. 2019.PubMed/NCBI View Article : Google Scholar | |
Gerich J, Fonseca V and Alvarado-Ruiz R: Monotherapy with GLP-1 receptor agonist, Lixisenatide, significantly improves glycaemic control in type 2 diabetic patients. In: Diabetologia. Springer, New York, NY, 2010. | |
Sanofi-Aventis UJB, NJ, Sanofi-Aventis US LLC: LLC: Adlyxin (Lixisenatide)[Prescribing Information], 2016. | |
LP APJW, DE: AstraZeneca Pharmaceuticals LP: Imfinzi (durvalumab) injection, for intravenous use [prescribing information], 2017. | |
Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E and Maffioli P: Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. Diabet Med. 29:1515–1523. 2012.PubMed/NCBI View Article : Google Scholar | |
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K and Davies MJ: Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 19:524–536. 2017.PubMed/NCBI View Article : Google Scholar | |
Chun E, Siojo A, Rivera D, Reyna K, Legere H, Joseph R and Pojednic R: Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes Obes Metab. 27:1536–1543. 2025.PubMed/NCBI View Article : Google Scholar | |
Kalra S: Choosing appropriate glucagon-like peptide 1 receptor agonists: A patient-centered approach. Diabetes Ther. 5:333–340. 2014.PubMed/NCBI View Article : Google Scholar | |
GlaxoSmithKline G: Tanzeum (albiglutide) prescribing informtion, 2015. | |
Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY and de la Peña A: Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: Analyses of data from clinical trials. Clin Pharmacokinet. 55:625–634. 2016.PubMed/NCBI View Article : Google Scholar | |
Montanya E and Sesti G: A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 31:2472–2488. 2009.PubMed/NCBI View Article : Google Scholar | |
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M and Wilding JPH: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 392:637–649. 2018.PubMed/NCBI View Article : Google Scholar | |
Onge ES, Miller SA and Motycka C: Liraglutide (Saxenda®) as a treatment for obesity. Food Nutr Sci. 7:227–235. 2016. | |
Chavda VP, Ajabiya J, Teli D, Bojarska J and Apostolopoulos V: Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review. Molecules. 27(4315)2022.PubMed/NCBI View Article : Google Scholar | |
Cai W, Zhang R, Yao Y, Wu Q and Zhang J: Tirzepatide as a novel effective and safe strategy for treating obesity: A systematic review and meta-analysis of randomized controlled trials. Front Public Health. 12(1277113)2024.PubMed/NCBI View Article : Google Scholar | |
Feier CVI, Vonica RC, Faur AM, Streinu DR and Muntean C: Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: A systematic literature review. Int J Mol Sci. 25(4346)2024.PubMed/NCBI View Article : Google Scholar | |
Yang XD and Yang YY: Clinical pharmacokinetics of semaglutide: A systematic review. Drug Des Devel Ther. 18:2555–2570. 2024.PubMed/NCBI View Article : Google Scholar |